Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Trelleborg – page 29

453 clinical trials in Trelleborg, Sweden across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Trelleborg at a glance
453
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

453 trials in Trelleborg

Open in trial search

Study on Synovial Hypertrophy in Patients with Hemophilia A Using Efanesoctocog Alfa Prophylaxis

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Study on the Safety of Decidua Stromal Cells for Patients with Steroid-Resistant Severe Acute Graft vs Host Disease

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Placenta-Derived Decidual Stromal Cells, Ex-Vivo Expanded
  • Sponsor:Oslo University Hospital HF

Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Novartis Pharma AG

Study on Siplizumab and Rabbit Anti-Thymocyte Globulin for Preventing Rejection in New Kidney Transplant Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Itb-Med AB

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Asthma

Not recruiting

Study on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Investigational
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Londamocitinib xinafoate
  • Sponsor:AstraZeneca AB

Factor VIII deficiency+1

Not recruiting

Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Colorectal cancer+6

Not recruiting

Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280
  • Sponsor:Incyte Corp.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Trelleborg

What the registry says about research in the country

01 Analytical and Diagnostic Research

Clinical trial activity in Trelleborg includes analytical and diagnostic research focused on better understanding treatment response and patient outcomes in everyday practice.

  • Assessment of symptom improvement in allergic rhinitis due to dog allergy
  • Monitoring clinical response to allergen-specific vaccination
  • Evaluation of outcome measures used to track effectiveness in routine care

These studies aim to improve how clinicians identify benefit and measure changes in patients over time.

02 Allergy and Immune System Diseases

One major focus is immune system diseases, especially allergic rhinitis due to dog allergy, with research designed to test whether targeted allergy treatment can reduce symptoms and improve quality of life.

  • Dog allergy and related nasal symptoms
  • Allergen immunotherapy in real-world Swedish practice
  • Long-term relief of allergy-related discomfort

This work explores the effectiveness of a new approach for helping patients manage persistent allergy symptoms.

03 Musculoskeletal Diseases

Another key area is musculoskeletal diseases, particularly research linked to hip arthroplasty and prevention of prosthetic joint infection.

  • Prosthetic Joint Infection after joint replacement
  • Strategies to lower infection risk following hip replacement
  • Support for safer recovery in orthopedic care

The goal is to evaluate whether infection-preventing bone graft treatment can improve outcomes after surgery.

04 Bacterial Infections and Surgical Procedures

Research in bacterial infections and surgical procedures is centered on preventing post-operative complications and improving the success of orthopedic treatment.

  • Prevention of infection in bone graft use
  • Protection against bacteria-related complications after surgery
  • Testing a treatment approach designed to support surgical recovery

These trials help clarify whether infection-focused interventions can make operative care safer and more effective.

05 Musculoskeletal and Neural Physiological Phenomena

The local research profile also reflects interest in musculoskeletal and neural physiological phenomena, with clinical studies examining how the body responds to allergy treatment and orthopedic interventions.

  • Changes in symptoms and function over time
  • Patient response after allergen treatment
  • Recovery patterns following joint replacement

In Trelleborg, these studies aim to connect physiological changes with practical benefits for patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.